AbbVie Pipeline Offers Multiple Means Of Protection Against Humira Sales Erosion
This article was originally published in The Pink Sheet Daily
Executive Summary
Hepatitis C combo is just one of AbbVie’s late-stage pipeline prospects to cover losses from generic competition to TriCor/Trilipix and the threat of biosimilar competition to Humira. It also has ABT-199, daclizumab and elagolix in Phase III studies.